MPS Ltd

MPS announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 22 August 2026.

MPS will hold a meeting of the Board of Directors of the Company on 21 July 2026.

MPS announced that Deepti Singh has tendered her resignation from the position of Chief People Officer and Senior Management Personnel of the Company, with effect from the close of business hours on 09 October 2026.

The Board of MPS at the meeting held on 15th May 2026, has decided not to recommend a final dividend for the financial year 2025-26.

Net profit of MPS declined 0.06% to Rs 47.04 crore in the quarter ended March 2026 as against Rs 47.07 crore during the previous quarter ended March 2025. Sales rose 12.66% to Rs 205.16 crore in the quarter ended March 2026 as against Rs 182.11 crore during the previous quarter ended March 2025. For the full year,net profit rose 16.33% to Rs 173.22 crore in the year ended March 2026 as against Rs 148.91 crore during the previous year ended March 2025. Sales rose 5.71% to Rs 768.37 crore in the year ended March 2026 as against Rs 726.89 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales205.16182.11 13 768.37726.89 6 OPM %32.9130.76 -30.6929.01 - PBDT72.9162.87 16 249.42222.63 12 PBT64.5555.99 15 221.65195.22 14 NP47.0447.07 0 173.22148.91 16 Powered by Capital Market - Live

MPS will hold a meeting of the Board of Directors of the Company on 15 May 2026.

MPS announced that its wholly owned subsidiary, MPS North America LLC has concluded the acquisition of 100% stake in Unbound Medicine Inc., USA for a total consideration of USD 16.5 million. Accordingly, Unbound Medicine, Inc., USA has become a wholly-owned step-down subsidiary of MPS. Powered by Capital Market - Live

Net profit of MPS declined 12.80% to Rs 35.50 crore in the quarter ended December 2025 as against Rs 40.71 crore during the previous quarter ended December 2024. Sales declined 2.08% to Rs 182.49 crore in the quarter ended December 2025 as against Rs 186.36 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales182.49186.36 -2 OPM %31.5532.38 - PBDT59.3961.96 -4 PBT53.0955.09 -4 NP35.5040.71 -13 Powered by Capital Market - Live

The acquisition will be executed through MPS North America LLC, a wholly owned subsidiary of MPS. The transaction is expected to be completed on or before 10 February 2026, subject to the fulfilment of customary closing conditions, the company said in a regulatory filing. The acquisition will be carried out for a cash consideration of $16.50 million, subject to customary adjustments. Founded in 1999, Unbound Medicine provides digital medical reference tools, clinical decision-support solutions and healthcare learning platforms. Its services are delivered through proprietary mobile and web-based platforms and follow a subscription-led institutional business model. The company serves medical schools, hospital systems and healthcare associations across the United States and Canada. MPS said the acquisition aligns with its strategy of building platform-led, recurring-revenue businesses. The transaction is expected to support revenue diversification, enable cross-selling opportunities and strengthen the company's presence in the North American market. MPS provides learning and platform solutions combining content, technology and artificial intelligence. The company is focused on scaling operations and strengthening its position in the global learning and knowledge services market. On a consolidated basis, net profit of MPS rose 57.32% to Rs 55.44 crore while net sales rose 9.42% to Rs 194.44 crore in Q2 September 2025 over Q2 September 2024. Powered by Capital Market - Live

The acquisition will be executed through MPS North America LLC, a wholly owned subsidiary of MPS. The transaction is expected to be completed on or before 10 February 2026, subject to the fulfilment of customary closing conditions, the company said in a regulatory filing. The acquisition will be carried out for a cash consideration of $16.50 million, subject to customary adjustments. Founded in 1999, Unbound Medicine provides digital medical reference tools, clinical decision-support solutions and healthcare learning platforms. Its services are delivered through proprietary mobile and web-based platforms and follow a subscription-led institutional business model. The company serves medical schools, hospital systems and healthcare associations across the United States and Canada. MPS said the acquisition aligns with its strategy of building platform-led, recurring-revenue businesses. The transaction is expected to support revenue diversification, enable cross-selling opportunities and strengthen the company's presence in the North American market. MPS provides learning and platform solutions combining content, technology and artificial intelligence. The company is focused on scaling operations and strengthening its position in the global learning and knowledge services market. On a consolidated basis, net profit of MPS rose 57.32% to Rs 55.44 crore while net sales rose 9.42% to Rs 194.44 crore in Q2 September 2025 over Q2 September 2024. Shares of MPS rose 3.46% to settle at Rs 1884.80 on Friday, 30 January 2026. Powered by Capital Market - Live